Monopar Appoints Commercial Leaders for ALXN1840 Launch
Monopar Therapeutics announced the addition of seasoned commercial leaders to its team, bolstering preparations for the anticipated launch of its first commercial product, ALXN1840. Nicole Sweeny was elected to the Board of Directors, bringing over 20 years of commercial leadership and rare disease launch experience. Additionally, Sharon Funk was appointed Senior Vice President, Sales and Marketing, and Daniel Olmstead was appointed Senior Vice President, Market Access, Distribution and Patient Services, both with extensive biopharmaceutical commercial experience. These strategic hires aim to support the potential commercialization of ALXN1840, a treatment for Wilson disease, for which the company plans to submit an FDA New Drug Application in mid-2026.
Key Highlights
- Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, elected to Monopar's Board of Directors.
- Sharon Funk appointed Senior Vice President, Sales and Marketing, bringing over 20 years of commercial leadership.
- Daniel Olmstead appointed Senior Vice President, Market Access, Distribution and Patient Services, with over 30 years of experience.
- These appointments strengthen Monopar's commercial team ahead of the anticipated launch of ALXN1840.
- ALXN1840 is a first-in-class treatment for Wilson disease, with an FDA New Drug Application planned for mid-2026.
Price Impact
More from MNPR